European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS)

Europace

Volumn 19, Issue 2, 2017, Pages 190-225

  Gorenek, Bulent ^a   Pelliccia, Antonio ^b   Benjamin, Emelia J ^c   Boriani, Giuseppe ^d   Crijns, Harry J ^e   Fogel, Richard I ^f   Van Gelder, Isabelle C ^g   Halle, Martin ^h   Kudaiberdieva, Gulmira ^c   Lane, Deirdre A ⁱ   Larsen, Torben Bjerregaard ^j   Lip, Gregory Y H ⁱ   Løchen, Maja Lisa ^k,l   Marín, Francisco ^m   Niebauer, Josef ⁿ   Sanders, Prashanthan ^o   Tokgozoglu, Lale ^p   Vos, Marc A ^q   VanWagoner, David R ^r   Fauchier, Laurent ^s   Savelieva, Irina ^t,u   Goette, Andreas ^u   Agewall, Stefan ^v   Chiang, Chern En ^w   Figueiredo, Marcio ^x   Stiles, Martin ^y   Dickfeld, Timm ^c   Patton, Kristen ^z   Piepoli, Massimo ^aa   Corra, Ugo ^ab   Marques Vidal, Pedro Manuel ^ac   Faggiano, Pompilio ^ad   Schmid, Jean Paul ^ae   Abreu, Ana ^af   more..

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^b Institute of Sports Medicine and Science   (Italy)

^c University of Modena and Reggio Emilia ^*  (United States)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f St Vincent Medical Group   (United States)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^j AALBORG UNIVERSITY HOSPITAL   (Denmark)

^k UNIVERSITY OF TROMSØ   (Norway)

^l AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

^m HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

ⁿ PARACELSUS MEDICAL UNIVERSITY   (Austria)

^o ROYAL ADELAIDE HOSPITAL   (Australia)

^p HACETTEPE UNIVERSITY   (Turkey)

^q UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^r LERNER RESEARCH INSTITUTE   (United States)

^s SERVICE DE DERMATOLOGIE   (France)

^t ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^u St Vincenz Hospital   (Germany)

^v ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^w TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^x UNIVERSITY OF CAMPINAS   (Brazil)

^y WAIKATO HOSPITAL   (New Zealand)

^z UNIVERSITY OF WASHINGTON   (United States)

^aa Department of Cardiology G da Saliceto Polichirurgico Hospital   (Italy)

^ab IRCCS   (Italy)

^ac LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^ad Azienda AO Spedali Civili di Brescia   (Italy)

^ae Spital Bern Tiefenau   (Switzerland)

^af HOSPITAL DE SANTA MARTA   (Portugal)

more..

Author keywords

Air pollution; Alcohol; Arrhythmias; Atrial fibrillation; Caffeine; Diabetes; Diet; Hyperlipidaemia; Hypertension; Obesity; Obstructive sleep apnoea; Physical activity; Prevention; Psychological distress; Recreational drugs; Risk factors; Smoking

Indexed keywords

ALCOHOL; CAFFEINE; FISH OIL; LIPID; RECREATIONAL DRUG;

AIR POLLUTION; ALCOHOL CONSUMPTION; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIET; DIETARY SUPPLEMENT; DISTRESS SYNDROME; DRUG THERAPY; ELECTROPHYSIOLOGY; ENDOCRINE DISEASE; FISH; FOOD INTAKE; GENETIC PREDISPOSITION; HEALTH ECONOMICS; HUMAN; HYPERTENSION; HYPERTHYROIDISM; LIPID BLOOD LEVEL; MEDICAL SOCIETY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; OBESITY; PATIENT PREFERENCE; PHYSICAL ACTIVITY; PHYSICAL INACTIVITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SLEEP DISORDERED BREATHING; SMOKING; SUPRAVENTRICULAR PREMATURE BEAT; SUPRAVENTRICULAR TACHYCARDIA; SYSTEMATIC REVIEW (TOPIC); THROMBOEMBOLISM; CARDIOLOGY; COMORBIDITY; CONSENSUS; LIFESTYLE; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; PREVENTIVE MEDICINE; RISK REDUCTION; STANDARDS; TREATMENT OUTCOME;

ATRIAL FIBRILLATION; CARDIOLOGY; COMORBIDITY; CONSENSUS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIFE STYLE; PREVENTIVE HEALTH SERVICES; PREVENTIVE MEDICINE; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 85016202063     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euw242     Document Type: Review

References (326)

1. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham Study. Neurology 1978;28:973-7.
2. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-up Study. Am J Med 1995;98:476-84.
3. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study: The Rotterdam Study. Stroke 1997;28:316-21.
4. Miyasaka Y, Barnes ME, Petersen RC, Cha SS, Bailey KR, Gersh BJ et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur Heart J 2007;28:1962-7.
5. Soliman EZ, Lopez F, O'Neal WT, Chen LY, Bengtson L, Zhang ZM et al. Atrial fibrillation and risk of ST-segment-elevation versus non-ST-segment-elevation myocardial infarction: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 2015;131:1843-50.
6. Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med 2014; 174:107-14.
7. Benjamin EJ,Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998;98:946-52.
8. Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A et al. Prevention of atrial fibrillation: report from a National Heart, Lung, and Blood Institute workshop. Circulation 2009;119:606-18.
9. Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda JG, Van Gelder IC. The cost of illness of atrial fibrillation: A systematic review of the recent literature. Europace 2011;13:1375-85.
10. Boriani G, Maniadakis N, Auricchio A, Müller-Riemenschneider F, Fattore G, Leyva F et al. Health technology assessment in interventional electrophysiology and device therapy: A position paper of the European Heart Rhythm Association. Eur Heart J 2013;34:1869-74.
11. Maniadakis N, Vardas P, Mantovani LG, Fattore G, Boriani G. Economic evaluation in cardiology. Europace 2011;13(Suppl 2):ii3-8.
12. Fattore G, Maniadakis N, Mantovani LG, Boriani G. Health technology assessment: what is it? Current status and perspectives in the field of electrophysiology. Europace 2011;13(Suppl 2):ii49-53.
13. Boriani G, Diemberger I, Martignani C, Biffi M, Branzi A. The epidemiological burden of atrial fibrillation: A challenge for clinicians and health care systems. Eur Heart J 2006;27:893-4.
14. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study. Lancet 2015;386:154-62.
15. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ et al. Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation 2014;129:837-47.
16. Boriani G, Diemberger I. Globalization of the epidemiologic, clinical, and financial burden of atrial fibrillation. Chest 2012;142:1368-70.
17. Weintraub WS, Daniels SR, Burke LE, Franklin BA, Goff DC Jr, Hayman LL et al. Value of primordial and primary prevention for cardiovascular disease: A policy statement from the American Heart Association. Circulation 2011;124:967-90.
18. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2011;123:1501-8.
19. Dave D, Kaestner R. Health insurance and ex ante moral hazard: evidence from Medicare. Int J Health Care Finance Econ 2009;9:367-90.
20. Dublin S, French B, Glazer NL, Wiggins KL, Lumley T, Psaty BM et al. Risk of newonset atrial fibrillation in relation to body mass index. Arch Intern Med 2006;166: 2322-8.
21. Long MJ, Jiang CQ, Lam TH, Xu L, Zhang WS, Lin JM et al. Atrial fibrillation and obesity among older Chinese: The Guangzhou Biobank Cohort Study. Int J Cardiol 2011;148:48-52.
22. Tedrow UB, Conen D, Ridker PM, Cook NR, Koplan BA, Manson JE et al. The long-and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (Women's Health Study). J Am Coll Cardiol 2010;55:2319-27.
23. Wang TJ, Parise H, Levy D, D'Agostino RB Sr,Wolf PA, Vasan RS et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004;292:2471-7.
24. Frost L, Benjamin EJ, Fenger-Grøn M, Pedersen A, Tjønneland A, Overvad K. Body fat, body fat distribution, lean body mass and atrial fibrillation and flutter. A Danish cohort study. Obesity (Silver Spring) 2014;22:1546-52.
25. Vermond RA, Geelhoed B, Verweij N, Tieleman RG, Van der Harst P, Hillege HL et al. Incidence of atrial fibrillation and relation with cardiovascular events, heart failure and mortality-A community-based study from the Netherlands. J Am Coll Cardiol 2015;66:1000-7.
26. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: A randomized clinical trial. JAMA 2013;310:2050-60.
27. Pathak RK, Elliot A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R et al. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: The CARDIO-FIT study. J Am Coll Cardiol 2015;66: 985-96.
28. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX et al. Long-term Effect of Goal-Directed Weight Management in an Atrial Fibrillation cohort: A long-term follow-up study (LEGACY). J Am Coll Cardiol 2015;65: 2159-69.
29. Rienstra M, Sun JX, Lubitz SA, Frankel DS, Vasan RS, Levy D et al. Plasma resistin, adiponectin, and risk of incident atrial fibrillation : The Framingham Offspring Study. Am Heart J 2012;163:119-24.
30. Nyrnes A, Mathiesen EB, Njolstad I, Wilsgaard T, Lochen ML. Palpitations are predictive of future atrial fibrillation. An 11-year follow-up of 22,815 men and women: The Tromso study. Eur J Prev Cardiol 2013;20:729-36.
31. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and casecontrol studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011;108:56-62.
32. Coromilas J. Obesity and atrial fibrillation: is one epidemic feeding the other? JAMA 2004;292:2519-20.
33. Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Lip GY, Larsen TB. Body mass index and adverse events in patients with incident atrial fibrillation. Am J Med 2013; 126:640.e9-17.
34. Badheka AO, Rathod A, Kizilbash MA, Garg N, Mohamad T, Afonso L et al. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med 2010;123:646-51.
35. Shen J, Johnson VM, Sullivan LM, Jacques PF, Magnani JW, Lubitz SA et al. Dietary factors and incident atrial fibrillation: The Framingham Heart Study. Am J Clin Nutr 2011;93:261-6.
36. Khawaja O, Gaziano JM, Djousse L. Nut consumption and risk of atrial fibrillation in the Physicians' Health Study. Nutr J 2012;11:17.
37. Fretts AM, Mozaffarian D, Siscovick DS, Heckbert SR, McKnight B, King IB et al. Associations of plasma phospholipid and dietary alpha linoleic acid with incident atrial fibrillation in older adults: The Cardiovascular Health Study. J Am Heart Assoc 2013;2:e003814.
38. Costanzo S, De Curtis A, di Niro V, Olivieri M, Morena M, De Filippo CM et al. on behalf of the Polyphemus Observational Study Investigators. Postoperative atrial fibrillation and total dietary antioxidant capacity in patients undergoing cardiac surgery: The Polyphemus Observational Study. J Thorac Cardiovasc Surg 2015; 149:1175-82.
39. Mattioli AV, Miloro C, Pennella S, Pedrazzi P, Farinetti A. Adherence to Mediterranean diet and intake of antioxidants influence spontaneous conversion of atrial fibrillation. Nutr Metab Cardiovasc Dis 2013;23:115-21.
40. Pastori D, Carnevale R, Barimoccia S, Nocella C, Tanzilli G, Cangemi R et al. Does Mediterranean diet reduce cardiovascular events and oxidative stress in atrial fibrillation? Antioxid Redox Signal 2015;23:682-7.
41. Martínez-González MA, Toledo E, Aró s F, Fiol M, Corella D, Salas-Salvadó J et al. Extra-virgin olive oil consumption reduces risk of atrial fibrillation. The PREDIMED (Prevención con Dieta Mediterránea) Trial. Circulation 2014;130:18-26.
42. Al Suwaidi J, Zubaid M, Al-Mahmeed WA, Al-Rashdan I, Amin H, Bener A et al. Impact of fasting in Ramadan in patients with cardiac disease. Saudi Med J 2005; 26:1579-83.
43. Van Wagoner DR, Piccini JP, Albert CM, Anderson ME, Benjamin EJ, Brundel B et al. Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. Heart Rhythm 2015;12:e5-29.
44. Lopez FL, Agarwal SK, Maclehose RF, Soliman EZ, Sharrett AR, Huxley RR et al. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: The Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol 2012;5:155-62.
45. Alonso A, Yin X, Roetker NS, Magnani JW, Kronmal RA, Ellinor PT et al. Blood lipids and the incidence of atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis and the Framingham Heart Study. J Am Heart Assoc 2014;3:e001211.
46. Gronroos NN, Chamberlain AM, Folsom AR, Soliman EZ, Agarwal SK, Nettleton JA et al. Fish, fish-derived n-3 fatty acids, and risk of incident atrial fibrillation in the Atherosclerosis Risk in Communities (ARIC) study. PLoS One 2012; 7:e36686.
47. Rix TA, Joensen AM, Riahi S, Lundbye-Christensen S, Tjønneland A, Schmidt EB et al. A U-shaped association between consumption of marine n-3 fatty acids and development of atrial fibrillation/atrial flutter-A Danish cohort study. Europace 2014;16:1554-61.
48. Rix TA, Joensen AM, Riahi S, Lundbye-Christensen S, Overvad K, Schmidt EB. Marine n-3 fatty acids in adipose tissue and development of atrial fibrillation: A Danish cohort study. Heart 2013;99:1519-24.
49. Virtanen JK, Mursu J, Voutilainen S, Tuomainen TP. Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation 2009;120:2315-21.
50. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003;92:1379-83.
51. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004;110:2313-9.
52. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004;62:105-11.
53. Elgendy IY, Mahmoud A, Huo T, Beaver TM, Bavry AA. Meta-analysis of 12 trials evaluating the effects of statins on decreasing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2015;115:1523-8.
54. Jacob KA, Nathoe HM, Dieleman JM, van Osch D, Kluin J, van Dijk D. Inflammation in new-onset atrial fibrillation after cardiac surgery: A systematic review. Eur J Clin Invest 2014;44:402-28.
55. Rahimi K, Emberson J, McGale P, MajoniW, Merhi A, Asselbergs FW et al. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 2011;342:d1250.
56. Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol 2013;28:7-18.
57. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S1-45.
58. Mozaffarian D, Psaty BM, Rimm EB, Lemaitre RN, Burke GL, Lyles MF et al. Fish intake and risk of incident atrial fibrillation. Circulation 2004;110:368-73.
59. Sakabe M, Shiroshita-Takeshita A, Maguy A, Dumesnil C, Nigam A, Leung TK et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation 2007;116:2101-9.
60. Mayyas F, Sakurai S, Ram R, Rennison JH, Hwang ES, Castel L et al. Dietary omega3 fatty acids modulate the substrate for post-operative atrial fibrillation in a canine cardiac surgery model. Cardiovasc Res 2011;89:852-61.
61. Mozaffarian D, Wu JH, de Oliveira Otto MC, Sandesara CM, Metcalf RG, Latini R et al. Fish oil and post-operative atrial fibrillation: A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2013;61:2194-6.
62. Darghosian L, Free M, Li J, Gebretsadik T, Bian A, Shintani A et al. Effect of omegathree polyunsaturated fatty acids on inflammation, oxidative stress, and recurrence of atrial fibrillation. Am J Cardiol 2015;115:196-201.
63. Nigam A, Talajic M, Roy D, Nattel S, Lambert J, Nozza A et al. Fish oil for the reduction of atrial fibrillation recurrence, inflammation and oxidative stress. J Am Coll Cardiol 2014;64:1441-8.
64. Visioli F, Rise P, Barassi MC, Marangoni F, Galli C. Dietary intake of fish vs. formulations leads to higher plasma concentrations of n-3 fatty acids. Lipids 2003;38: 415-8.
65. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Europace 2010; 12:1360-420.
66. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2960-84.
67. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013;177:1006-14.
68. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008;118:1080-111.
69. Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007;49:565-71.
70. Cadby G, McArdle N, Briffa T, Hillman DR, Simpson L, KnuimanMet al. Severity of OSA is an independent predictor of incident atrial fibrillation hospitalization in a large sleep-clinic cohort. Chest 2015;148:945-52.
71. Arias MA, Sánchez AM, Alonso-Fernández A, García-Río F. Atrial fibrillation, obesity, and obstructive sleep apnea. Arch Intern Med 2007;167:1552-3.
72. Ghias M, Scherlag BJ, Lu Z, Niu G, Moers A, Jackman WM et al. The role of ganglionated plexi in apnea-related atrial fibrillation. J Am Coll Cardiol 2009;54: 2075-83.
73. Roche F, Xuong AN, Court-Fortune I, Costes F, Pichot V, Duverney D et al. Relationship among the severity of sleep apnea syndrome, cardiac arrhythmias, and autonomic imbalance. Pacing Clin Electrophysiol 2003;26:669-77.
74. Fein AS, Shvilkin A, Shah D, Haffajee CI, Das S, Kumar K et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 2013;62:300-5.
75. Neilan TG, Farhad H, Dodson JA, Shah RV, Abbasi SA, Bakker JP et al. Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation. J Am Heart Assoc 2013;2:e000421.
76. GrimmW, Hoffmann J, Menz V, Köhler U, Heitmann J, Peter JH et al. Electrophysiologic evaluation of sinus node function and atrioventricular conduction in patients with prolonged ventricular asystole during obstructive sleep apnea. Am J Cardiol 1996;77:1310-4.
77. Simantirakis EN, Schiza SI, Marketou ME, Chrysostomakis SI, Chlouverakis GI, Klapsinos NC et al. Severe bradyarrhythmias in patients with sleep apnoea: The effect of continuous positive airway pressure treatment: A long-term evaluation using an insertable loop recorder. Eur Heart J 2004;25:1070-6.
78. Naruse Y, Tada H, Satoh M, Yanagihara M, Tsuneoka H, Hirata Y et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: clinical impact of continuous positive airway pressure therapy. Heart Rhythm 2013;10:331-7.
79. Li L,Wang ZW, Li J, Ge X, Guo LZ,Wang Y et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: A meta-analysis of observational studies. Europace 2014;16:1309-14.
80. Khan A, Latif F, Hawkins B, Tawk M, Sivaram CA, Kinasewitz G. Effects of obstructive sleep apnea treatment on left atrial volume and left atrial volume index. Sleep Breath 2008;12:141-7.
81. Maeno K, Kasagi S, Ueda A, Kawana F, Ishiwata S, OhnoMet al. Effects of obstructive sleep apnea and its treatment on signal-averaged P-wave duration in men. Circ Arrhythm Electrophysiol 2013;6:287-93.
82. Arias MA, García-Río F, Alonso-Fernández A, Mediano O, Martínez I, Villamor J. Obstructive sleep apnea syndrome affects left ventricular diastolic function: effects of nasal continuous positive airway pressure in men. Circulation 2005;112: 375-83.
83. Shukla A, Aizer A, Holmes D, Fowler S, Park DS, Bernstein S et al. Effect of obstructive sleep apnea treatment on atrial fibrillation recurrence: A meta-analysis. JACC-CEP 2015;1:41-51.
84. Cowie MR,Woehrle H,Wegscheider K, Angermann C, d'Ortho MP, Erdmann E et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med 2015;373:1095-105.
85. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA et al. Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study. JAMA 1994;271:840-4.
86. Thomas MD, Dublin S, Kaplan RC, Glazer NL, Lumley T, Longstreth WT Jr et al. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens 2008; 21:1111-6.
87. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study. J Am Coll Cardiol 2005;45:712-9.
88. Marott SCW, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of atrial fibrillation: A nationwide study. Eur Heart J 2014;35:1205-14.
89. Okin PM, Hille DA, Larstorp ACK,Wachtell K, Kjeldsen SE, Dahlof B et al. Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. Hypertension 2015;66:368-73.
90. The GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606-17.
91. Goette A, Schon N, Kirchhof P, Breithardt G, Fetsch T, Hausler KG et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 2012;5:43-51.
92. Lip GY, Frison L, Grind M. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation. J Intern Med 2007;261:577-86.
93. Emdin CA, Callender T, Cao J, Rahimi K. Effect of antihypertensive agents on risk of atrial fibrillation: A meta-analysis of large-scale randomized trials. Europace 2015;17:701-10.
94. Gillis AM. Angiotensin-receptor blockers for prevention of atrial fibrillation-A matter of timing or target? N Engl J Med 2009;360:1669-71.
95. Mayyas F, Alzoubi KH, Van Wagoner DR. Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int J Cardiol 2013;168:5135-42.
96. Khatib R, Joseph P, Briel M, Yusuf S, Healey J. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of nonvalvular atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 2013;165:17-24.
97. Menezes AR, Lavie CJ, DiNicolantonio JJ, O'Keefe J, Morin DP, Khatib S et al. Atrial fibrillation in the 21st century: A current understanding of risk factors and primary prevention strategies. Mayo Clin Proc 2013;88:394-409.
98. Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: The CHARGE-AF consortium. J Am Heart Assoc 2013;2: e000102.
99. Huxley RR, Alonso A, Lopez FL, Filion KB, Agarwal SK, Loehr LR et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: The Atherosclerosis Risk in Communities study. Heart 2012;98:133-8.
100. Ostgren CJ, Merlo J, Rastam L, Lindblad U. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 2004;6:367-74.
101. Pfister R, Michels G, Cairns R, Schneider CA, Erdmann E. Incidence of new onset bundle branch block and atrial fibrillation in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive study. Int J Cardiol 2011; 153:233-4.
102. Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk of incident atrial fibrillation in women. J Am Coll Cardiol 2012;60:1421-8.
103. Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med 2010; 25:853-8.
104. Aksnes TA, Schmieder RE, Kjeldsen SE, Ghani S, Hua TA, Julius S. Impact of new onset diabetes mellitus on development of atrial fibrillation and heart failure in high risk hypertension (from the VALUE Trial). Am J Cardiol 2008;101:634-8.
105. Chang SH, Wu LS, Chiou MJ, Liu JR, Yu KH, Kuo CF et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: A population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol 2014; 13:123.
106. Overvad TF, Skjøth F, Lip GYH, Lane DA, Albertsen IE, Rasmussen LH et al. Duration of diabetes mellitus and risk of thromboembolism and bleeding in atrial fibrillation: nationwide cohort study. Stroke 2015;46:2168-74.
107. Anselmino M, Matta M, D'ascenzo F, Pappone C, Santinelli V, Bunch TJ et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus: A systematic review and meta-analysis. Europace 2015;17:1518-25.
108. Chamberlain AM, Agarwal SK, Folsom AR, Duval S, Soliman EZ, Ambrose M et al. Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm 2011;8:1160-6.
109. Pfister R, Bragelmann J, Michels G,Wareham NJ, Luben R, Khaw KT. Performance of the CHARGE-AF risk model for incident atrial fibrillation in the EPIC Norfolk cohort. Eur J Prev Cardiol 2015;22:932-9.
110. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003;14:666-72.
111. Everett BM, Cook NR, Conen D, Chasman DI, Ridker PM, Albert CM. Novel genetic markers improve measures of atrial fibrillation risk prediction. Eur Heart J 2013;34:2243-51.
112. Rodriguez CJ, Soliman EZ, Alonso A, Swett K, Okin PM, Goff DC Jr et al. Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: The Multi-Ethnic Study of Atherosclerosis. Ann Epidemiol 2015;25:71-6.
113. Suzuki S, Otsuka T, Sagara K, Kano H, Matsuno S, Takai H et al. Association between smoking habits and the first-time appearance of atrial fibrillation in Japanese patients: evidence from the Shinken database. J Cardiol 2015;66:73-9.
114. Heeringa J, Kors JA, Hofman A, van Rooij FJ, Witteman JC. Cigarette smoking and risk of atrial fibrillation: The Rotterdam study. Am Heart J 2008;156:1163-9.
115. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): A community-based cohort study. Lancet 2009;373:739-45.
116. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997;96: 2455-61.
117. Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health study. Am J Med 2005; 118:489-95.
118. Wilhelmsen L, Rosengren A, Lappas G. Hospitalizations for atrial fibrillation in the general male population: Morbidity and risk factors. J Intern Med 2001;250:382-9.
119. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001;86: 516-21.
120. Hergens MP, Galanti R, Hansson J, Fredlund P, Ahlbom A, Alfredsson L et al. Use of Scandinavian moist smokeless tobacco (snus) and the risk of atrial fibrillation. Epidemiology 2014;25:872-6.
121. Dixit S, Pletcher MJ, Vittinghoff E, Imburgia K, Maguire C, Whitman IR et al. Second hand smoke and atrial fibrillation: data from the health Eheart study. Heart Rhythm 2016;13:3-9.
122. Okumura Y. Smoking and the risk of the perpetuation of atrial fibrillation: under debate in large cohort studies. Heart Rhythm 2011;8:1167-8.
123. Monroy AE, Hommel E, Smith ST, Raji M. Paroxysmal atrial fibrillation following electronic cigarette use in an elderly woman. Clin Geriatr 2012;20:28-32.
124. O'Neal WT, Qureshi WT, Judd SE, McClure LA, Cushman M, Howard VJ et al. Environmental tobacco smoke and atrial fibrillation: The REasons for Geographic And Racial Differences in Stroke (REGARDS) Study. J Occup Environ Med 2015; 57:1154-8.
125. Rigotti NA, Eagle KA. Atrial fibrillation while chewing nicotine gum. JAMA 1986; 255:1018.
126. Stewart PM, Catterall JR. Chronic nicotine ingestion and atrial fibrillation. Br Heart J 1985;54:222-3.
127. Choragudi NL, Aronow WS, DeLuca AJ. Nicotine gum-induced atrial fibrillation. Heart Dis 2003;5:100-1.
128. Levitzky YS, Guo CY, Rong J, Larson MG,Walter RE, Keaney JF Jr et al. Relation of smoking status to a panel of inflammatory markers: The Framingham offspring. Atherosclerosis 2008;201:217-24.
129. Tuan TC, Chang SL, Tai CT, Lin YJ, Hu YF, Lo LWet al. Impairment of the atrial substrates by chronic cigarette smoking in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2008;19:259-65.
130. Hayashi H, Omichi C, Miyauchi Y, Mandel WJ, Lin SF, Chen PS et al. Age-related sensitivity to nicotine for inducible atrial tachycardia and atrial fibrillation. Am J Physiol Heart Circ Physiol 2003;285:H2091-8.
131. Goette A. Nicotine, atrial fibrosis, and atrial fibrillation: do microRNAs help to clear the smoke? Cardiovasc Res 2009;83:421-2.
132. Goette A, Lendeckel U, Kuchenbecker A, Bukowska A, Peters B, Klein HU et al. Cigarette smoking induces atrial fibrosis in humans via nicotine. Heart 2007;93: 1056-63.
133. Shan H, Zhang Y, Lu Y, Zhang Y, Pan Z, Cai B et al. Downregulation of mir-133 and mir-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res 2009;83:465-72.
134. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen city heart study. Eur Respir J 2003;21: 1012-6.
135. Li J, Agarwal SK, Alonso A, Blecker S, Chamberlain AM, London SJ et al. Airflow obstruction, lung function, and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 2014;129:971-80.
136. Bosdriesz JR, Willemsen MC, Stronks K, Kunst AE. Socioeconomic inequalities in smoking cessation in 11 European countries from 1987 to 2012. J Epidemiol Community Health 2015;69:886-92.
137. Hitchman SC, Fong GT, Zanna MP, Thrasher JF, Chung-Hall J, Siahpush M. Socioeconomic status and smokers' number of smoking friends: Findings from the international tobacco control (itc) four-country survey. Drug Alcohol Depend 2014; 143:158-66.
138. Zoller B, Li X, Sundquist J, Sundquist K. Neighbourhood deprivation and hospitalization for atrial fibrillation in Sweden. Europace 2013;15:1119-27.
139. Misialek JR, Rose KM, Everson-Rose SA, Soliman EZ, Clark CJ, Lopez FL et al. Socioeconomic status and the incidence of atrial fibrillation in whites and blacks: The Atherosclerosis Risk in Communities (ARIC) study. J Am Heart Assoc 2014;3: e001159.
140. Piccini JP, Hammill BG, Sinner MF, Hernandez AF, Walkey AJ, Benjamin EJ et al. Clinical course of atrial fibrillation in older adults: The importance of cardiovascular events beyond stroke. Eur Heart J 2014;35:250-6.
141. Schnabel RB, Rienstra M, Sullivan LM, Sun JX, Moser CB, Levy D et al. Risk assessment for incident heart failure in individuals with atrial fibrillation. Eur J Heart Fail 2013;15:843-9.
142. Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Lip GY. Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: The Belgrade atrial fibrillation study. Eur J Heart Fail 2013;15:415-24.
143. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010;41:2731-8.
144. Nakagawa K, Hirai T, Ohara K, Fukuda N, Numa S, Taguchi Y et al. Impact of persistent smoking on long-term outcomes in patients with nonvalvular atrial fibrillation. J Cardiol 2015;65:429-33.
145. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study. JAMA 2003;290:1049-56.
146. Angoulvant D, Villejoubert O, Bejan-Angoulvant T, Ivanes F, Saint Etienne C, Lip GY et al. Effect of active smoking on comparative efficacy of antithrombotic therapy in patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project. Chest 2015;148:491-8.
147. Huang Y, Britton J, Hubbard R, Lewis S. Who receives prescriptions for smoking cessation medications? An association rule mining analysis using a large primary care database. Tob Control 2013;22:274-9.
148. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: The ARREST-AF cohort study. J Am Coll Cardiol 2014;64: 2222-31.
149. Newby DE, Mannucci PM, Tell GS, Baccarelli AA, Brook RD, Donaldson K et al. ESC Working Group on Thrombosis, European Association for Cardiovascular Prevention and Rehabilitation; ESC Heart Failure Association. Expert position paper on air pollution and cardiovascular disease. Eur Heart J 2015;36:83-93b.
150. Rajagopalan S, Brook RD. Air pollution and type 2 diabetes: mechanistic insights. Diabetes 2012;61:3037-45.
151. Brook RD, Rajagopalan S, Pope CA, III Bhatnagar A, Diez-Roux AV, Holguin F et al. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. Circulation 2010;121: 2331-78.
152. Brook RD, Rajagopalan S. Particulate matter, air pollution, and blood pressure. J Am Soc Hypertens 2009;3:332-50.
153. Pope CA III, Turner MC, Burnett RT, Jerrett M, Gapstur SM, Diver WR et al. Relationships between fine particulate air pollution, cardiometabolic disorders, and cardiovascular mortality. Circ Res 2015;116:108-15.
154. Peters A, Frohlich M, Doring A, Immervoll T, Wichmann HE, Hutchinson WLet al. Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study. Eur Heart J 2001;22:1198-204.
155. Wellenius GA, Burger MR, Coull BA, Schwartz J, Suh HH, Koutrakis P et al. Ambient air pollution and the risk of acute ischemic stroke. Arch Intern Med 2012;172: 229-34.
156. O'Donnell MJ, Fang J, Mittleman MA, Kapral MK, Wellenius GA. Fine particulate air pollution (PM2.5) and the risk of acute ischemic stroke. Epidemiology 2011;22: 422-31.
157. Wellenius GA, Schwartz J, Mittleman MA. Air pollution and hospital admissions for ischemic and hemorrhagic stroke among medicare beneficiaries. Stroke 2005;36:2549-53.
158. Milojevic A, Wilkinson P, Armstrong B, Bhaskaran K, Smeeth L, Hajat S. Shortterm effects of air pollution on a range of cardiovascular events in England and Wales: case-crossover analysis of the MINAP database, hospital admissions and mortality. Heart 2014;100:1093-8.
159. Bunch TJ, Horne BD, Asirvatham SJ, Day JD, Crandall BG, Weiss JP et al. Atrial fibrillation hospitalization is not increased with short-term elevations in exposure to fine particulate air pollution. Pacing Clin Electrophysiol 2011;34:1475-9.
160. Link MS, Luttmann-Gibson H, Schwartz J, Mittleman MA, Wessler B, Gold DR et al. Acute exposure to air pollution triggers atrial fibrillation. J Am Coll Cardiol 2013;62:816-25.
161. Rich DQ, Mittleman MA, Link MS, Schwartz J, Luttmann-Gibson H, Catalano PJ et al. Increased risk of paroxysmal atrial fibrillation episodes associated with acute increases in ambient air pollution. Environ Health Perspect 2006;114:120-3.
162. Rashid A, Hines M, Scherlag BJ, Yamanashi WS, LovalloW. The effects of caffeine on the inducibility of atrial fibrillation. J Electrocardiol 2006;39:421-5.
163. Newcombe PF, Renton KW, Rautaharju PM, Spencer CA, Montague TJ. Highdose caffeine and cardiac rate and rhythm in normal subjects. Chest 1988;94:90-4.
164. Strubelt O, Diederich KW. Experimental treatment of the acute cardiovascular toxicity of caffeine. J Toxicol Clin Toxicol 1999;37:29-33.
165. Donnerstein RL, Zhu D, Samson R, Bender AM, Goldberg SJ. Acute effects of caffeine ingestion on signal-averaged electrocardiograms. Am Heart J 1998;136(4 Pt 1):643-6.
166. Conen D, Chiuve SE, Everett BM, Zhang SM, Buring JE, Albert CM. Caffeine consumption and incident atrial fibrillation in women. Am J Clin Nutr 2010;92:509-14.
167. Frost L, Vestergaard P. Caffeine and risk of atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study. Am J Clin Nutr 2005;81:578-82.
168. Caldeira D, Martins C, Alves LB, Pereira H, Ferreira JJ, Costa J. Caffeine does not increase the risk of atrial fibrillation: A systematic review and meta-analysis of observational studies. Heart 2013;99:1383-9.
169. Di R Jr, During A, Morelli PJ, Heyden M, Biancaniello TA. Atrial fibrillation in healthy adolescents after highly caffeinated beverage consumption: two case reports. J Med Case Rep 2011;5:18.
170. Ettinger PO, Wu CF, De La Cruz C Jr,Weisse AB, Ahmed SS, Regan TJ. Arrhythmias and the 'Holiday Heart': alcohol-associated cardiac rhythm disorders. Am Heart J 1978;95:555-62.
171. Liang Y, Mente A, Yusuf S, Gao P, Sleight P, Zhu J et al. Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease. CMAJ 2012;184:E857-66.
172. Mandyam MC, Vedantham V, Scheinman MM, Tseng ZH, Badhwar N, Lee BK et al. Alcohol and vagal tone as triggers for paroxysmal atrial fibrillation. Am J Cardiol 2012;110:364-8.
173. Laszlo R, Eick C, Schwiebert M, Schreiner B, Weig HJ, Weretka S et al. Alcohol-induced electrical remodeling: effects of sustained short-termethanol infusion on ion currents in rabbit atrium. Alcohol Clin Exp Res 2009;33:1697-703.
174. Maki T, Toivonen L, Koskinen P, Naveri H, Harkonen M, Leinonen H. Effect of ethanol drinking, hangover, and exercise on adrenergic activity and heart rate variability in patients with a history of alcohol-induced atrial fibrillation. Am J Cardiol 1998;82:317-22.
175. Mukamal KJ, Tolstrup JS, Friberg J, Jensen G, Gronbaek M. Alcohol consumption and risk of atrial fibrillation in men and women: The Copenhagen City Heart Study. Circulation 2005;112:1736-42.
176. Conen D, Tedrow UB, Cook NR, Moorthy MV, Buring JE, Albert CM. Alcohol consumption and risk of incident atrial fibrillation in women. JAMA 2008;300: 2489-96.
177. Djousse L, Levy D, Benjamin EJ, Blease SJ, Russ A, Larson MG et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol 2004;93:710-3.
178. Larsson SC, Drca N,Wolk A. Alcohol consumption and risk of atrial fibrillation: A prospective study and dose-response meta-analysis. J Am Coll Cardiol 2014;64: 281-9.
179. Kodama S, Saito K, Tanaka S, Horikawa C, Saito A, Heianza Y et al. Alcohol consumption and risk of atrial fibrillation: A meta-analysis. J Am Coll Cardiol 2011;57: 427-36.
180. Conen D, Albert CM. Alcohol consumption and risk of atrial fibrillation: how much is too much? J Am Coll Cardiol 2014;64:290-2.
181. Devlin R, Henry JA. Clinical review: major consequences of illicit drug consumption. Crit Care 2008;12:202.
182. Korantzopoulos P, Liu T, Papaioannides D, Li G, Goudevenos JA. Atrial fibrillation and marijuana smoking. Int J Clin Pract 2008;62:308-13.
183. Krishnamoorthy S, Lip GY, Lane DA. Alcohol and illicit drug use as precipitants of atrial fibrillation in young adults: A case series and literature review. Am J Med 2009; 122:851-6.e3.
184. Madhok A, Boxer R, Chowdhury D. Atrial fibrillation in an adolescent-the agony of ecstasy. Pediatr Emerg Care 2003;19:348-9.
185. Furlanello F, Serdoz LV, Cappato R, Ambroggi LD. Illicit drugs and cardiac arrhythmias in athletes. Eur J Cardiovasc Prev Rehab 2007;14:487-94.
186. Lau DH, Stiles MK, Shashidhar BJ, Glenn D, Young GD, Sanders P. Atrial fibrillation and anabolic steroid abuse. Int J Cardiol 2007;117:e86-7.
187. Kaakeh Y, Overholser BR, Lopshire JC, Tisdale JE. Drug-induced atrial fibrillation. Drugs 2012;72:1617-30.
188. Guglin M, Aljayeh M, Saiyad S, Ali R, Curtis AB. Introducing a new entity: chemotherapy-induced arrhythmia. Europace 2009;11:1579-86.
189. Schjerning Olsen AM, Fosbøl EL, Pallisgaard J, Lindhardsen J, Lock Hansen M, Køber L et al. NSAIDs are associated with increased risk of atrial fibrillation in patients with prior myocardial infarction: A nationwide study. Eur Heart J Cardiovasc Pharmacother 2015;1:107-14.
190. Sharma A, Einstein AJ, Vallakati A, Arbab-Zadeh A,Walker MD, MukherjeeDet al. Risk of atrial fibrillation with use of oral and intravenous bisphosphonates. Am J Cardiol 2014;113:1815-21.
191. Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC. Bisphosphonates and risk of cardiovascular events: A meta-analysis. PLoS One 2015;10:e0122646.
192. Yalaci S, Tamer A, Kocayigit I, Gunduz H. Atrial fibrillation due to olanzapine overdose. Clin Toxicol 2011;49:440.
193. Martin RI, Pogoryelova O, Koref MS, Bourke JP, Teare MD, Keavney BD. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart 2014;100:1506-10.
194. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol 2014;63:945-53.
195. McCabe PJ. Psychological distress in patients diagnosed with atrial fibrillation: The state of the science. J Cardiovasc Nurs 2010;25:40-51.
196. Thrall G, Lip GY, Carroll D, Lane D. Depression, anxiety, and quality of life in patients with atrial fibrillation. Chest 2007;132:1259-64.
197. Habibović M, Versteeg H, Pelle AJ, Theuns DA, Jordaens L, Pedersen SS. Poor health status and distress in cardiac patients: The role of device therapy vs. underlying heart disease. Europace 2013;15:355-61.
198. von Eisenhart Rothe A, Hutt F, Baumert J, Breithardt G, Goette A, Kirchhof P et al. Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: A longitudinal analysis--data from the German Competence Network on Atrial Fibrillation. Europace 2015;17:1354-62.
199. von Eisenhart Rothe AF, Goette A, Kirchhof P, Breithardt G, Limbourg T, CalvertMet al. Depression in paroxysmal and persistent atrial fibrillation patients: A cross-sectional comparison of patients enrolled in two large clinical trials. Europace 2014;16:812-9.
200. Gehi AK, Sears S, Goli N, Walker TJ, Chung E, Schwartz J et al. Psychopathology and symptoms of atrial fibrillation: implications for therapy. J Cardiovasc Electrophysiol 2012;23:473-8.
201. Patel D, Mc Conkey ND, Sohaney R, McNeil A, Jedrzejczyk A, Armaganijan L. A systematic review of depression and anxiety in patients with atrial fibrillation: The mind-heart link. Cardiovasc Psychiatry Neurol 2013;2013:159850.
202. Lip GY, Laroche C, Boriani G, Cimaglia P, Dan GA, Santini M et al. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: A report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace 2015;17:24-31.
203. Lampert R, Joska T, Burg MM, BatsfordWP, McPherson CA, Jain D. Emotional and physical precipitants of ventricular arrhythmia. Circulation 2002;106:1800-5.
204. Burg MM, Lampert R, Joska T, Batsford W, Jain D. Psychological traits and emotion-triggering of ICD shock-terminated arrhythmias. Psychosom Med 2004; 66:898-902.
205. WhangW, Albert CM, Sears SF Jr, Lampert R, Conti JB,Wang PJ et al. Depression as a predictor for appropriate shocks among patients with implantable cardioverter-defibrillators: results from the Triggers of Ventricular Arrhythmias (TOVA) study. J Am Coll Cardiol 2005;45:1090-5.
206. Eaker ED, Sullivan LM, Kelly-Hayes M, D'Agostino RB Sr, Benjamin EJ. Anger and hostility predict the development of atrial fibrillation in men in the Framingham Offspring Study. Circulation 2004;109:1267-71.
207. Eaker ED, Sullivan LM, Kelly-Hayes M, D'Agostino RB Sr, Benjamin EJ. Tension and anxiety and the prediction of the 10-year incidence of coronary heart disease, atrial fibrillation, and total mortality: The Framingham Offspring Study. Psychosom Med 2005;67:692-6.
208. WhangW, Davidson KW, Conen D, Tedrow UB, Everett BM, Albert CM. Global psychological distress and risk of atrial fibrillation among women: The Women's Health Study. J Am Heart Assoc 2012;1:e001107.
209. Qureshi WT, Alirhayim Z, Blaha MJ, Juraschek SP, Keteyian SJ, Brawner CA et al. Cardiorespiratory fitness and risk of incident atrial fibrillation: results from the Henry Ford Exercise Testing (FIT) Project. Circulation 2015;131:1827-34.
210. Drca N,Wolk A, Jensen-Urstad M, Larsson SC. Physical activity is associated with a reduced risk of atrial fibrillation in middle-aged and elderly women. Heart 2015; 101:1627-30.
211. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: The Cardiovascular Health Study. Circulation 2008;118:800-7.
212. Grimsmo J, Grundvold I, Maehlum S, Arnesen H. High prevalence of atrial fibrillation in long-term endurance cross-country skiers: echocardiographic findings and possible predictors-A 28-30 years follow-up study. Eur J Cardiovasc Prev Rehabil 2010;17:100-5.
213. Myrstad M, NystadW, Graff-Iversen S, Thelle DS, Stigum H, Aarønæs M et al. Effect of years of endurance exercise on risk of atrial fibrillation and atrial flutter. Am J Cardiol 2014;114:1229-33.
214. Lee DC, Pate RR, Lavie CJ, Sui X, Church TS, Blair SN. Leisure-time running reduces all-cause and cardiovascular mortality risk. J Am Coll Cardiol 2014;64: 472-81.
215. Thelle DS, Selmer R, Gjesdal K, Sakshaug S, Jugessur A, Graff-Iversen S et al. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: A prospective study of 309,540 men and women. Heart 2013;99:1755-60.
216. Aizer A, Gaziano JM, Cook NR, Manson JE, Buring JE, Albert CM. Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol 2009;103:1572-7.
217. Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res 2014;114:1453-68.
218. Coumel P. Paroxysmal atrial fibrillation: A disorder of autonomic tone? Eur Heart J 1994;15(Suppl A):9-16.
219. D'Ascenzi F, Cameli M, Padeletti M, Lisi M, Zacà V, Natali B et al. Characterization of right atrial function and dimension in top-level athletes: A speckle tracking study. Int J Cardiovasc Imaging 2013;29:87-94.
220. D'Andrea A, Riegler L, Cocchia R, Scarafile R, Salerno G, Gravino R et al. Left atrial volume index in highly trained athletes. Am Heart J 2010;159:1155-61.
221. Brugger N, Krause R, Carlen F, Rimensberger C, Hille R, Steck H et al. Effect of lifetime endurance training on left atrial mechanical function and on the risk of atrial fibrillation. Int J Cardiol 2014;170:419-25.
222. Benito B, Gay-Jordi G, Serrano-Mollar A, Guasch E, Shi Y, Tardif JC et al. Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation 2011;123:13-22.
223. Lindsay MM, Dunn FG. Biochemical evidence of myocardial fibrosis in veteran endurance athletes. Br J Sports Med 2007;41:447-52.
224. De Vos CB, Nieuwlaat R, Crijns HJ, Camm AJ, LeHeuzey JY, Kirchhof CJ et al. Autonomic trigger patterns and antiarrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. Eur Heart J 2008;29:632-9.
225. O'Keefe JH, Schnohr P, Lavie CJ. The dose of running that best confers longevity. Heart 2013;99:588-90.
226. Schnohr P, Marott JL, Lange P, Jensen GB. Longevity in male and female joggers: The Copenhagen City Heart Study. Am J Epidemiol 2013;177:683-9.
227. Ofman P, Khawaja O, Rahilly-Tierney CR, Peralta A, Hoffmeister P, Reynolds MR et al. Regular physical activity and risk of atrial fibrillation: A systematic review and meta-analysis. Circ Arrhythm Electrophysiol 2013;6:252-6.
228. Kwok CS, Anderson SG, Myint PK, Mamas MA, Loke YK. Physical activity and incidence of atrial fibrillation: A systematic review and meta-analysis. Int J Cardiol 2014;177:467-76.
229. Mont L, Elosua R, Brugada J. Endurance sport practice as a risk factor for atrial fibrillation and atrial flutter. Europace 2009;11:11-7.
230. Calvo N, Ramos P, Montserrat S, Guasch E, Coll-Vinent B, Domenech M et al. Emerging risk factors and the dose-response relationship between physical activity and lone atrial fibrillation: A prospective case-control study. Europace 2016;18: 57-63.
231. Drca N,Wolk A, Jensen-Urstad M, Larsson SC. Atrial fibrillation is associated with different levels of physical activity levels at different ages in men. Heart 2014;100: 1037-42.
232. Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis. Europace 2009;11: 1156-9.
233. Edelmann F, Gelbrich G, Düngen HD, Fröhling S,Wachter R, Stahrenberg R et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 2011;58:1780-91.
234. Alings M, Smit MD, Moes ML, Crijns HJ, Tijssen JG, Brugemann J et al. Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: Background, aims and design of the RACE 3 study. Neth Heart J 2013; 21:354-63.
235. Darbar D, Herron KJ, Ballew JD, Jahangir A, Gersh PG, Shen WK et al. Familial AF is a genetically heterogeneous disorder. J Am Coll Cardiol 2003;41:2185-92.
236. Fox CS, Parise H, D'Agostino RB Sr, Lloyd-Jones DM, Vasan RS, Wang TJ et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2004;291:2851-5.
237. Arnar DO, Thorvaldsson S, Manolio TA, Thorgeirsson G, Kristjansson K, Hakonarson H et al. Familial aggregation of atrial fibrillation in Iceland. Eur Heart J 2006;27:708-12.
238. Gundlund A, Christiansen MN, Hansen ML, Olesen JB, Zahir D, Køber L et al. Familial clustering and subsequent incidence of atrial fibrillation among first-degree relatives in Denmark. Europace 2016;18:658-64.
239. Zöller B, Ohlsson H, Sundquist J, Sundquist K. High familial risk of atrial fibrillation/atrial flutter in multiplex families: A nationwide family study in Sweden. J Am Heart Assoc 2012;2:e003384.
240. Lubitz SA, Yin X, Fontes JD, Magnani JW, Rienstra M, Pai M et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA 2010; 304:2263-9.
241. Oyen N, Ranthe MF, Carstensen L, Boyd HA, Olesen MS, Olesen SP et al. Familial aggregation of lone atrial fibrillation in young persons. J Am Coll Cardiol 2012;60: 917-21.
242. Brugada R, Tappscot T, Czernuszewicz GZ, Marian AJ, Iglesias A, Mont L et al. Identification of a genetic locus for familial atrial fibrillation. New Engl J Med 1997;336:905-11.
243. Tucker NP, Ellinor PT. Emerging directions in genetics of atrial fibrillation. Circ Res 2014;114:1462-82.
244. Sinner MF, Tucker NR, Lunetta KL, Ozaki K, Smith JG, Trompet S et al. Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation. Circulation 2014;130:1225-35.
245. Smith JG, Almgren P, Engstrom G, Hedblad B, Platonov PG, Newton-Cheh C et al. Genetic polymorphisms for estimating risk of atrial fibrillation: A literature-based meta-analysis. J Intern Med 2012;272:573-82.
246. Mohanty S, Santangeli P, Bai R, Di Biase L, Mohanty P, Pump A et al. Variant rs2200733 on chromosome 4q25 confers increased risk of atrial fibrillation: evidence from a meta-analysis. J Cardiovasc Electrophysiol 2013;24:155-61.
247. Kirchhof P, Breithardt G, Aliot E, Al Khatib S, Apostolakis S, Auricchio A et al. Personalized management of atrial fibrillation: proceedings from the fourth atrial fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace 2013;15:1540-56.
248. Fabritz L, Guasch E, Antoniades C, Bardinet I, Benninger G, Betts TR et al. Expert consensus document: defining the major health modifiers causing atrial fibrillation: A roadmap to underpin personalized prevention and treatment. Nat Rev Cardiol 2016;13:230-7.
249. Selmer C, Olesen JB, Hansen ML, Lindhardsen J, Schjerning Olsen AM, Clausager J et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: A large population cohort study. BMJ 2012;345:e7895.
250. Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter. A population-based study. Arch Intern Med 2004;164:1675-8.
251. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke JL et al. Thyroid status, cardiovascular risk and mortality in older adults. JAMA 2006;295:1033-41.
252. Kim EJ, Lyass A,Wang N, Massaro JM, Fox CS, Benjamin EJ et al. Relation of hypothyroidism and incident atrial fibrillation (from the Framingham Heart Study). Am Heart J 2014;167:123-6.
253. Auer J, Scheibner P, Mische T, LangstegerW, Eber O, Eber B. Subclinical hypothyroidism as a risk factor for atrial fibrillation. Am Heart J 2001;142:838-42.
254. Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FDR, Wilson S et al. Association between free thyroxine concentration and atrial fibrillation. Arch Intern Med 2007;167:928-34.
255. Sawin CT, Geller A,Wolf PA, Belander AJ, Baker E, Bacharach P et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249-52.
256. Collet TH, Gussekloo J, Bauer DC, den Elzen WPJ, Wendy PJ, Cappola AR et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012;172:799-809.
257. Heeringa J, Hoogendoorn EH, van der Deure WM, Hofman A, Peeters RP, Hop WCJ et al. High-normal thyroid function and risk of atrial fibrillation. Arch Intern Med 2008;168:2219-24.
258. Chaker L, Heeringa J, Dehghan A, Medici M, Visser WE, Baumgartner C et al. Normal thyroid function and the risk of atrial fibrillation: The Rotterdam Study. J Clin Endocrinol Metab 2015;100:3718-24.
259. Von Olshausen K, Bischoff S, Kahaly G, Mohr-Kahaly S, Erbel R, Beyer J et al. Cardiac arrhythmias and heart rate in hyperthyroidism. Am J Cardiol 1989;63:930-3.
260. Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 1982;72:903-6.
261. Siu CW, Jim MH, Zhang X, Chan YH, Pong V, Kwok J et al. Comparison of atrial fibrillation recurrence rates after successful electrical cardioversion in patients with hyperthyroidism-induced versus non-hyperthyroidism-induced persistent atrial fibrillation. Am J Cardiol 2009;103:540-3.
262. Machino T, Tada H, Sekiguchi Y, Yamasaki H, Kuroki K, Igarashi M et al. Prevalence and influence of hyperthyroidism on the long-term outcome of catheter ablation for drug-refractory atrial fibrillation. Circ J 2012;76:2546-51.
263. Wongcharoen W, Lin YJ, Chang SL, Lo LW, Hu YF, Chung FP et al. History of hyperthyroidism and long-term outcome of catheter ablation of drug-refractory atrial fibrillation. Heart Rhythm 2015;12:1956-62.
264. Chan PH, Hai J, Yeung CY, Lip GY, Lam KS, Tse HF et al. Benefit of anticoagulation therapy in hyperthyroidism-related atrial fibrillation. Clin Cardiol 2015;38:476-82.
265. Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500-10.
266. Bruere H, Fauchier L, Bernard Brunet A, Pierre B, Simeon E, Babuty D et al. History of thyroid disorders in relation to clinical outcomes in atrial fibrillation. Am J Med 2015;128:30-7.
267. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66.
268. Voigt N, Dobrev D. Cellular and molecular correlates of ectopic activity in patients with atrial fibrillation. Europace 2012;14(Suppl 5):v97-v105.
269. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options-A report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 2012;14:8-27.
270. De Jong AM, Maass AH, Oberdorf-Maass SU, Van Veldhuisen DJ, Van Gilst WH, Van Gelder IC. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. Cardiovasc Res 2011;89:754-65.
271. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: A translational appraisal. Physiol Rev 2011;91:265-325.
272. Venteclef N, Guglielmi V, Balse E, Gaborit B, Cotillard A, Atassi F et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipofibrokines. Eur Heart J 2015;36:795-805.
273. Cosio FG, Aliot E, Botto GL, Heidbüchel H, Geller CJ, Kirchhof P et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace 2008;10:21-7.
274. Nattel S, Guasch E, Savelieva I. Early management of atrial fibrillation to prevent cardiovascular complications. Eur Heart J 2014;35:1448-56.
275. Wellens HJ, Durrer D. Wolff-Parkinson-White syndrome and atrial fibrillation. Relation between refractory period of accessory pathway and ventricular rate during atrial fibrillation. Am J Cardiol 1974;34:777-83.
276. Campbell RW, Smith RA, Gallagher JJ, Pritchett EL,Wallace AG. Atrial fibrillation in the preexcitation syndrome. Am J Cardiol 1977;40:514-22.
277. Hamer ME, Wilkinson WE, Clair WK, Page RL, McCarthy EA, Pritchett EL. Incidence of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia. J Am Coll Cardiol 1995;25:984-8.
278. Ozcan C, Strom JB, Newell JB, Mansour MC, Ruskin JN. Incidence and predictors of atrial fibrillation and its impact on long-term survival in patients with supraventricular arrhythmias. Europace 2014;16:1508-14.
279. Waldo AL. Mechanisms of atrial flutter and atrial fibrillation: distinct entities or two sides of a coin? Cardiovasc Res 2002;54:217-29.
280. Lin CH, Chang SL, Huang HK, Lo LW, Lin YJ, Chiang CH et al. Novel electrophysiological characteristics of atrioventricular nodal continuous conduction curves in atrioventricular nodal re-entrant tachycardia with concomitant cavotricuspid isthmus-dependent atrial flutter. Europace 2015;pii: euv345.
281. Chen YJ, Chen SA, Tai CT,Wen ZC, Feng AN, Ding YA et al. Role of atrial electrophysiology and autonomic nervous system in patients with supraventricular tachycardia and paroxysmal atrial fibrillation. J Am Coll Cardiol 1998;32:732-8.
282. Sticherling C, Oral H, Horrocks J, Chough SP, Baker RL, Kim MH et al. Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness. Circulation 2000;102:2503-8.
283. Crijns HJGM, Lie KI. Hemodynamic deterioration after treatment with adenosine. Br Heart J 1995;73:103.
284. Nabar A, Rodriguez LM, Timmermans C, Van den Dool A, Smeets JLRM, Wellens HJJ. Observations in four patient groups having type I atrial flutter with or without associated atrial fibrillation. Circulation 1999;99:1441-5.
285. Pentinga ML, Meeder JG, Crijns HJGM, De Muinck ED, Wiesfeld ACP, Lie KI. Late onset atrioventricular nodal tachycardia. Int J Cardiol 1993;38:293-8.
286. Wellens HJ. When to perform catheter ablation in asymptomatic patients with a Wolff-Parkinson-White electrocardiogram. Circulation 2005;112:2201-16.
287. McKenna W. Hypertrophic cardiomyopathy. Lancet 2004;363:1881-91.
288. Haissaguerre M, Fischer B, Labbé T, Lemétayer P, Montserrat P, d'Ivernois C et al. Frequency of recurrent atrial fibrillation after catheter ablation of overt accessory pathways. Am J Cardiol 1992;69:493-7.
289. Pappone C, Santinelli V. Catheter ablation should be performed in asymptomatic patients with Wolff-Parkinson-White syndrome. Circulation 2005;112:2207-16.
290. McKeown PP, Gutterman D. Executive summary: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 2005;128:1S-5S.
291. Shariff N, Zelenkofske S, Eid S, Weiss MJ, Mohammed MQ. Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after CABG surgery. BMC Cardiovasc Disord 2010;8:10-7.
292. Shantsila E, Watson T, Lip GY. Atrial fibrillation post-cardiac surgery: changing perspectives. Curr Med Res Opin 2006;22:1437-41.
293. Sánchez-Quinõnes J, Marín F, Roldán V, Lip GY. The impact of statin use on atrial fibrillation. QJM 2008;101:845-61.
294. Nair SG. Atrial fibrillation after cardiac surgery. Ann Card Anaesth 2010;13: 196-205.
295. Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: A meta-analysis. Circulation 2002;106:75-80.
296. Jidéus L, BlomströmP, Nilsson L, Stridsberg M, Hansell P, Blomström-Lundqvist C. Tachyarrhythmias and triggering factors for atrial fibrillation after coronary artery bypass operations. Ann Thorac Surg 2000;69:1064-9.
297. Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GMet al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev 2013;1:CD003611.
298. Bagshaw SM, Galbraith PD, Mitchell LB, Sauve R, Exner DV, GhaliWA. Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: A meta-analysis. Ann Thorac Surg 2006;82:1927-37.
299. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006;114:1455-61.
300. ESC Press Release Office. STICS-Short-term peri-operative statin treatment does not reduce complications after cardiac surgery. 02 Sep 2014. http://www. escardio.org/The-ESC/Press-Office/Press-releases/Last-5-years/STICS-Shortterm-peri-operative-statin-treatment-does-not-reduce-complications (6 December 2015, date last accessed).
301. Orenes-Pinero E, Montoro-García S, Banerjee A, Valdés M, Lip GYH, Marín F. Pre and post-operative treatments for prevention of atrial fibrillation after cardiac surgery. Mini Rev Med Chem 2012;12:1419-31.
302. Ho KM, Tan JA. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: A dose-response meta-analysis. Circulation 2009;119:1853-66.
303. Savelieva I, Kakouros N, Kourliouros A, Camm JA. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 2011; 13:308-28.
304. Savelieva I, Kakouros N, Kourliouros A, Camm JA. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace 2011;13:610-25.
305. Madrid AH, Bueno MG, Rebollo JM, Marín I, Pena G, Bernal E et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002;106:331-6.
306. Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012;59:1598-603.
307. Liu T, Korantzopoulos P, Shao Q, Zhang Z, Letsas KP, Li G. Mineralocorticoid receptor antagonists and atrial fibrillation: A meta-analysis. Europace 2016;18:672-8.
308. Lip GYHL, Lane D. Stroke prevention in atrial fibrillation. A systematic review. JAMA 2015;313:1950-62.
309. Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboembolism in atrial fibrillation. Circ J 2012;76:2289-304.
310. Lip GYHL, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010;137:263-72.
311. Lamberts M, Nielsen OW, Lip GY, Ruwald MH, Christiansen CB, Kristensen SL et al. Cardiovascular risk in patients with sleep apnoea with or without continuous positive airway pressure therapy: follow-up of 4.5 million Danish adults. J Intern Med 2014;276:659-66.
312. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: The Swedish Atrial Fibrillation Cohort study. Eur Heart J 2015;36:297-306.
313. Agarwal M, Apostolakis S, Lane DA, Lip GY. The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: A systematic review. Clin Ther 2014;36:1135-44.
314. Lip GYHL, Frison L, Grind M. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 2007;28:752-9.
315. Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Albertsen IE, Lane DA et al. Alcohol intake and prognosis of atrial fibrillation. Heart (Br Card Soc) 2013;99: 1093-9.
316. Albertsen IE, Rasmussen LH, Lane DA, Overvad TF, Skjoth F, Overvad K et al. The impact of smoking on thromboembolism and mortality in patients with incident atrial fibrillation: insights from the Danish Diet, Cancer, and Health study. Chest 2014;145:559-66.
317. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012;14:528-606.
318. Bunch TJ, May HT, Bair TL, Weiss JP, Crandall BG, Osborn JS et al. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm 2013;10:1272-7.
319. De Caterina R, Husted S,Wallentin L, Andreotti F, Arnesen H, Bachmann F et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESCWorking Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;110:1087-107.
320. Gallego P, Roldan V, Marin F, Romera M, Valdes M, Vicente V et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013;110:1189-98.
321. Azoulay L, Dell'Aniello S, Simon TA, Renoux C, Suissa S. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J 2014; 35:1881-7.
322. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: The SAMe-TT(2)R(2) score. Chest 2013;144:1555-63.
323. Proietti M, Lip GY. Simple decision making between a vitamin K Antagonist and Non-Vitamin K Antagonist Oral Anticoagulant (NOACs): using the SAMe-TT2R2 Score. Eur Heart J Cardiovasc Pharmacother 2015;1:150-2.
324. Dogliotti A, Giugliano RP. A novel approach indirectly comparing benefit-risk balance across anti-thrombotic therapies in patients with atrial fibrillation. Eur Heart J Cardiovasc Pharmacother 2015;1:15-28.
325. Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMETT2R2score to poor quality anticoagulation, stroke, clinically relevant bleeding and mortality in patients with atrial fibrillation. Chest 2014;146:719-26.
326. Lane DA, Aguinaga L, Blomström-Lundqvist C, Boriani G, Dan GA, Hills MT et al. Cardiac tachyarrhythmias and patient values and preferences for their management: The European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiologi a (SOLEACE). Europace 2015;17:1747-69.